Release date: 2014-08-19
Recently, some scientists from Thailand and the United Kingdom have developed a new blood test method for identifying patients with drug-resistant malaria. This approach was based on previous research by researchers on the kelch13 gene mutation in patients with anti-artemisinin drug malaria. The kelch13 gene is a gene in the malaria parasite Plasmodium. Through a study of approximately 1,240 patients in Africa and South Asia, the researchers found that this new blood test method is aimed at both the kelch13 gene test and the results indicate that the test method is highly sensitive because almost all anti-artemisinin malaria cases There are mutations in the kelch13 gene.
The researchers further found that even drug-resistant Plasmodium still responds to artemisinin in long-term treatment. Therefore, the researchers suggest that in Africa and South Asia, patients should receive appropriate medication regardless of whether they exhibit symptoms of malaria. Of course, considering the cost issue, this proposal is still debatable. But this work will undoubtedly push the world's anti-malaria work even further. According to the US Centers for Disease Control and Prevention, there are about 1,500 confirmed cases of malaria each year in the United States. The WHO has a total of 219 million malaria cases worldwide and caused 660,000 deaths. This result was published in The New England Journal of Medicine.
Source: Bio Valley
We are a professional Chinese manufacturer of Anti-Cancer Ingredients;we supply various products of Anti-Tumor Materials, and can providing product images and basic parameters with each Anti-Neoplasm Ingredients and Anti-Mutation Ingredients, such as Betulinic Acid, Genipin 98%, Kaempferol 98%, Pterostilbene 98%. Look forward to your cooperation!
Anti-Tumor Materials,Betulinic Acid,Genipin 98%,Kaempferol 98%,Pterostilbene 98%
Xi'an Quanao Biotech Co., Ltd. , https://www.quanaobio.com